Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Nephrology
You have accessRestricted Access

Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study

Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Denise Ramjit, Tania Z. Dickson, Gilbert W. Gleim, Carl Erik Mogensen, Dick de Zeeuw, Barry M. Brenner and Steven M. Snapinn
JASN June 2005, 16 (6) 1775-1780; DOI: https://doi.org/10.1681/ASN.2004080632
Zhongxin Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahnaz Shahinfar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William F. Keane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Ramjit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tania Z. Dickson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilbert W. Gleim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Erik Mogensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dick de Zeeuw
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry M. Brenner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Snapinn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Information

vol. 16 no. 6 1775-1780
DOI 
https://doi.org/10.1681/ASN.2004080632
PubMed 
15872078

Published By 
American Society of Nephrology
Print ISSN 
1046-6673
Online ISSN 
1533-3450
History 
  • Received for publication August 3, 2004
  • Accepted for publication March 17, 2005
  • Published online May 25, 2005.

Article Versions

  • Earlier version (May 4, 2005 - 10:41).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2005 American Society of Nephrology

Author Information

  1. Zhongxin Zhang*,
  2. Shahnaz Shahinfar*,
  3. William F. Keane†,
  4. Denise Ramjit*,
  5. Tania Z. Dickson‡,
  6. Gilbert W. Gleim‡,
  7. Carl Erik Mogensen§,
  8. Dick de Zeeuw‖,
  9. Barry M. Brenner¶ and
  10. Steven M. Snapinn*
  1. *Cardiovascular Clinical Research, †Clinical Development, and ‡Medical Communications Department, Merck & Co., Inc., West Point, Pennsylvania; §Medical Department, Aarhus University Hospital, Aarhus, Denmark; ‖Clinical Pharmacology, University Medical Center Groningen, Groningen, Netherlands; and ¶Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts
  1. Address correspondence to:
    Dr. Zhongxin Zhang, Merck & Co., Inc., P.O. Box 4, BL 3–4, West Point, PA 19486. Phone: 484-344-3871; Fax: 484-344-4000; E-mail: zhongxin_zhang{at}merck.com
View Abstract

Statistics from Altmetric.com

Article usage

Article usage: May 2005 to December 2020

AbstractFullPdf
May 200520148161
Jun 2005361303230
Jul 20058111669
Aug 2005428425
Sep 2005278629
Oct 2005185526
Nov 2005315313
Dec 2005142415
Jan 20061868
Feb 2006131110
Mar 200639711
Apr 200631913
May 2006312226
Jun 2006123953
Jul 2006124027
Aug 2006143426
Sep 200692725
Oct 2006134131
Nov 200693926
Dec 20065189
Jan 200741918
Feb 200732317
Mar 2007132926
Apr 2007112023
May 2007113623
Jun 200773415
Jul 200772024
Aug 200792318
Sep 200792920
Oct 2007122415
Nov 2007143923
Dec 200743110
Jan 200891813
Feb 2008101514
Mar 2008102413
Apr 2008121716
May 2008163318
Jun 200893017
Jul 2008101617
Aug 200841411
Sep 20089227
Oct 2008102212
Nov 20088197
Dec 2008122214
Jan 20096177
Feb 20098199
Mar 2009163724
Apr 2009132220
May 2009122020
Jun 2009111422
Jul 200981417
Aug 20098720
Sep 200952115
Oct 2009102023
Nov 2009161621
Dec 2009131724
Jan 2010131114
Feb 201081121
Mar 201041123
Apr 2010131210
May 2010121413
Jun 2010389
Jul 201041915
Aug 201061913
Sep 201021221
Oct 2010111113
Nov 20101678
Dec 2010171320
Jan 201126921
Feb 2011272418
Mar 201112139
Apr 2011131111
May 2011251117
Jun 2011202918
Jul 2011242216
Aug 2011291513
Sep 201132710
Oct 2011261614
Nov 201133139
Dec 201117108
Jan 2012551814
Feb 201220117
Mar 201238109
Apr 2012381110
May 20122295
Jun 2012241412
Jul 2012211510
Aug 20122435
Sep 20121686
Oct 2012661313
Nov 2012231011
Dec 2012461910
Jan 2013743115
Feb 2013401411
Mar 2013551611
Apr 20133099
May 2013481510
Jun 201332810
Jul 2013291015
Aug 20132168
Sep 20131524
Oct 20133036
Nov 20131758
Dec 201322611
Jan 20142339
Feb 20143678
Mar 201454511
Apr 20143436
May 201437910
Jun 201430711
Jul 20142586
Aug 20142935
Sep 20143428
Oct 20141647
Nov 20143466
Dec 201417310
Jan 20151412
Feb 201515412
Mar 20152259
Apr 20151735
May 20151844
Jun 201525134
Jul 20153828
Aug 20152699
Sep 20152086
Oct 201515510
Nov 2015191311
Dec 2015920
Jan 201619911
Feb 20162292
Mar 201614510
Apr 201627516
May 201625414
Jun 201613816
Jul 201610711
Aug 20161356
Sep 2016714
Oct 20161447
Nov 20163284
Dec 20161377
Jan 20172498
Feb 201711104
Mar 2017585
Apr 201710148
May 20171159
Jun 2017953
Jul 20171198
Aug 2017660
Sep 20171661
Oct 2017760
Nov 2017975
Dec 2017850
Jan 2018266
Feb 2018323
Mar 2018815
Apr 2018838
May 2018624
Jun 2018835
Jul 2018835
Aug 2018911
Sep 2018374
Oct 2018262
Nov 2018072
Dec 2018383
Jan 2019340
Feb 20194103
Mar 201951212
Apr 2019193
May 20194116
Jun 20191205
Jul 20191109
Aug 20191123
Sep 20194147
Oct 2019256
Nov 2019364
Dec 20196116
Jan 2020072
Feb 20202148
Mar 2020152
Apr 2020254
May 2020176
Jun 2020064
Jul 2020440
Aug 2020153
Sep 20200104
Oct 20207237
Nov 2020596
Dec 2020383

Cited By...

  • 31 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (6)
Journal of the American Society of Nephrology
Vol. 16, Issue 6
1 Jun 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study
Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Denise Ramjit, Tania Z. Dickson, Gilbert W. Gleim, Carl Erik Mogensen, Dick de Zeeuw, Barry M. Brenner, Steven M. Snapinn
JASN Jun 2005, 16 (6) 1775-1780; DOI: 10.1681/ASN.2004080632

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study
Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Denise Ramjit, Tania Z. Dickson, Gilbert W. Gleim, Carl Erik Mogensen, Dick de Zeeuw, Barry M. Brenner, Steven M. Snapinn
JASN Jun 2005, 16 (6) 1775-1780; DOI: 10.1681/ASN.2004080632
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy
  • Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors
  • IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria
Show more Clinical Nephrology

Cited By...

  • Role of Remission Clinics in the Longitudinal Treatment of CKD
  • Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire